Analysis of lecanemab-LEQEMBI manufacturer’s research and development status and regular sales channels

Lecanemab (lecanemab)-LEQEMBI is a monoclonal antibody targeting β-amyloid protein (Aβ), jointly developed by Biogen and Eisai. Its mechanism of action is mainly by clearing early amyloid plaques in the brain, thereby slowing down the decline of cognitive function in patients with Alzheimer's disease (AD). The drug has been verified through multiple rounds of clinical trials, showing that it can significantly improve cognitive function scores and daily living abilities in early-stage and mild-to-moderate AD patients, and has a certain effect in delaying the progression of the disease.

In terms of production and research and development, lencanezumab is led by internationally renowned biopharmaceutical companies. The research and development team has accumulated rich experience in antibody design, clinical research and drug delivery systems. Through rigorous clinical trials and regulatory approvals, LEQEMBI has been approved in the United States, Europe and parts of Asia for the treatment of patients with early-stage Alzheimer's disease. Its research and development process emphasizes the balance between safety and effectiveness, and also conducts a systematic evaluation of patient tolerance for long-term use.

Regarding sales channels, lencanezumab is already on the market in China, but it has not yet been included in medical insurance reimbursement, and the supply of the drug is limited, making it relatively difficult for patients to obtain it. It is usually necessary to make an appointment and purchase a prescription through the neurology department or cognitive impairment center of a large tertiary hospital. In overseas markets, the US version of LEQEMBI is expensive, with each box selling for more than 10,000 yuan. Patients can obtain it through regular overseas drug purchase channels, but they must follow imported drug management regulations and prescription review procedures to ensure reliable sources of drugs.

In the practice of clinical use and drug purchase, patients and their families should fully understand the source and usage specifications of drugs and avoid obtaining drugs through informal channels. During use, it needs to be carried out under the guidance of a professional doctor, and cognitive function, imaging indicators and adverse reactions must be monitored regularly to ensure the efficacy and safety of the drug. At the same time, combined with life intervention and rehabilitation training, the clinical value of lencanezumab in the management of Alzheimer's disease can be maximized.

Keyword tags: Lencanezumab, Alzheimer's disease, β-Amyloid, domestically marketed, cognitive improvement

References:https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval